Efficacy of acetyldinaline treatment in the daunomycineresistant, Ara-C resistant or cyclophosphamide resistant BNML sublines compared to the BNML parental cell line
Group
Median BNML/P, parental BNML cell line; BNML/Dauno-R, daunomycineresistant BNML subline; BNML/Ara-C-R, cytosine arabinosideresistant BNML subline; BNML/CP-R, cyclophosphamide-resistant BNML subline. a IST increase in (median) survival time of treated rats vs control group. b LCK, log cell kill. The value is deduced from the known linear relationship between leukemic cell load reduction and the survival time, ie 4 days/log for the BNML/P cell line and 3 days/log for the 3 other cell lines.
controls was determined. The ISTs for each of the treatment groups was compared with that of the corresponding non-treated controls group. Based on the known relationship between cell load reduction and increase in survival time for each BNML subline the LCK induced by drug treatment can be deduced. Finally, the effect of ACD on the resistant cell line was compared in terms of LCK, with the efficacy of ACD in the parental BNML line. The survival curves for ACD treatment of the three BNML-resistant sublines and that of the parental BNML/P cell line are shown in Figure 1 . ACD treatment of rats carrying the BNML/P cell line resulted in an IST with 18 days (median survival time, MdST 45 days) compared to the non-treated control rats (MdST 27 days). ACD treatment group of rats injected with the BNML/Dauno-R subline resulted in an IST of 14 days (MdST 25 days) compared with the corresponding non-treated control group (MdST 11 days). ACD treatment of rats injected with the BNML/Ara-C-R subline resulted in an IST of 15 days (MdST 28 days) compared with the corresponding non-treated control group (MdST 13 days). ACD treatment of rats carrying the BNML/CP-R cell line resulted in an IST of 12 days (MdST 28 days) compared with the corresponding nontreated control group (MdST 16 days). In all groups all rats died from leukemia relapse. In Table 1 the leukemic cell load reducing effects of a single course of ACD treatment for each of the resistant sublines and for the BNML/P cell line are listed. For the BNML/P the 18 days increase in the survival time reflects a LCK of 4.5; for the BNML/Dauno-R the calculated LCK is 4.7; for the BNML-Ara-C-R 5.0 and for the BNML-CP-R line 4.0, respectively.
Sideroblastic anemia following treatment of chronic myeloid leukemia with busulfan

TO THE EDITOR
An increasing proportion of patients with myelodysplastic syndromes (MDS) have had previous exposure to chemotherapeutic agents, classically alkylating drugs, but recently also purine analogues, anthracyclines and epipodophyllotoxins. [1] [2] [3] [4] Most cases follow treatment after a median interval of 4-5 years and are associated with prominent dysplasia, mild to marked reticular fibrosis and cytogenetic These results show that the sublines of the BNML rat leukemia model that acquired resistance for either Dauno, Ara-C or CP during repeated in vivo administration of the respective drugs retained the sensitivity for ACD. During the treatment of AML the leukemic cells often acquire resistance to the frequently used drugs Dauno, Ara-C or CP. The exact mode of action of ACD is not yet known although there are reports that it affects intracellular amino acid transport thus interfering with protein metabolism, DNA synthesis and cell proliferation. 8 On the basis of the preclinical study reported here it is concluded that the mechanisms involved in the resistance to Dauno, Ara-C and CP, do not effect the susceptibility of the resistant cells for ACD. Clinical evaluation of ACD in acute leukemia, especially in leukemia patients resistant to those cytostatic drugs, is warranted.
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University abnormalities in chromosomes 5 and 7. Busulfan, as an alkylating agent, has a known leukemogenic potential. Evidence is suggestive that the increasing duration of chemotherapy and the cumulative dose of the drug influence the development of secondary MDS (s-MDS) and increase the risk of leukemogenesis. 1, 3 We report a patient with chronic myeloid leukemia (CML) who had received busulfan over a 2-month period and developed dysplastic features including sideroblastic erythropoiesis shortly after the drug was discontinued.
A 70-year-old woman presented with paleness, weight loss and a markedly enlarged spleen. Laboratory evaluation revealed hemoglobin 7.0 g/dl, WBC 250 × 10 9 /l (blasts 5%, myelocytes 1%, metamyelocytes 2%, bands 16%, segmented neutrophils 53%, eosinophils 10%, lymphocytes 6%, monocytes 7%) and platelets 930 × 10 9 /l. Bone marrow aspirate was compatible with CML. There was marked erythroid hypoplasia and no ringed sideroblasts were seen. The patient received busulfan 4 mg daily and allopurinol 300 mg daily. Ten weeks after initiating therapy, her WBC were 9.6 × 10 9 /l and the spleen was not palpable. Busulfan was discontinued and 4 months later her hemoglobin was 9.2 g/dl, WBC 2.7 × 10 9 /l, and platelets 43 × 10 9 /l. Bone marrow examination showed a normocellular marrow (30%), M:E ratio 1:2.5, moderate dyserythropoiesis, shift to immaturity of the granulocytes (Figure 1) and presence of micromegakaryocytes. Storage iron was markedly increased and there were 28% ringed sideroblasts (Figure 1) . The patient was placed on pyridoxine with no improvement in her peripheral blood count. Twenty-one months after the diagnosis of CML and 18 months after discontinuation of busulfan, cytogenetic analysis showed Philadelphia chromosome in 13/25 metaphases. Molecular analysis with the reverse transcriptase-polymerase chain reaction technique showed the presence of a b3a2/b2a2 fusion transcript. On this occasion hemoglobin was 11.8 mg/dl, WBC 5.2 × 10 9 /l with normal differential counts and platelet counts 120 × 10 9 /l. The bone marrow aspirate disclosed persistence of trilineage dysplasia. At this time, only rare ringed sideroblasts were observed.
In the present case, the diagnosis of typical CML was based on clinical and hematological features and later confirmed by cytogenetic and molecular analysis. 5, 6 In spite of a marked erythroid hypoplasia no ringed sideroblasts were seen at diagnosis. 7 After discontinuation of short-term therapy with busulfan, a long-lasting pancytopenia was observed. A bone marrow examination performed 4 months later showed normal cellularity with no reticular fibrosis but with dysplastic features and ringed sideroblasts. Neutropenia remitted spontaneously 18 months later. Bone marrow analysis showed persistent cell atypias and reversal of sideroblastic erythropoiesis. To our knowledge, this is the fourth case in the literature reporting sideroblastic changes related to busulfan exposure. 8 In at least one of these patients the abnormality was reversible, as was observed in our case. Although cytogenetic and molecular studies performed 18 months after therapy discontinuance showed no alterations other than that usually seen in CML, 5, 6 the persistent dysplastic hemopoiesis probably indicates permanent damage. There is still no evidence of an accelerated phase, blast crisis or a more aggressive disease over a 21-month follow-up, but these events cannot be ruled out.
Alkylating agents have a known myelotoxic effect, directly related to greater cumulative dose and longer duration of therapy. 3, 4 In the present case, the exposure to busulfan was very short and cumulative dose given was low before dysplastic hemopoiesis was detected. Although busulfan is especially damaging to stem cells, its relation to myelodysplasia and secondary acute myeloid leukemia soon after a short course of the drug has rarely been documented. Our findings
Figure 1
Bone marrow showing dyserythropoiesis and dysgranulopoiesis (left) and ringed sideroblasts (right) 4 months after discontinuation of busulfan.
Leukemia support a possible relationship between busulfan exposure and sideroblastic changes.
